9 May 2024
Target Healthcare REIT plc and its subsidiaries
("Target Healthcare" or "the Group")
Net Asset Value, update on corporate activity and dividend declaration
Target Healthcare (LSE: THRL), the
Corporate activity highlights
Continued EPRA NTA growth and sustainable earnings from prime care home real estate, an investment class underpinned by structural tailwinds and institutional investment demand:
· EPRA Net Tangible Assets ('NTA') per share increased 2.2% to
· EPRA "topped-up" net initial yield tightened marginally to 6.19% (31 December 2023: 6.25%)
· Adjusted EPRA EPS for the quarter of
· NAV total return of 3.6% for the quarter (based on EPRA NTA and including payment of dividend)
· Net LTV of 25.8% (31 December 2023: 25.8%)
· Weighted average debt term of 5.5 years (31 December 2023: 5.7 years) with the earliest maturity in November 2025. Interest costs hedged on 89% of drawn debt to the relevant facility maturity date
· Total capital available of
Rental growth driven by inflation-linked reviews and completion of two developments; valuation growth from strong underlying portfolio trading:
· Diversified portfolio of 98 assets let to 33 tenants and valued at
· Contracted rent roll increased by 3.7%, comprising a:
o 0.8% like-for-like increase driven by inflation-linked upwards-only annual rent reviews
o 2.9% increase from the practical completion of, and new 35-year leases agreed on, two developments
· WAULT of 26.0 years which remains one of the longest in the listed
· High quality, modern and sustainable real estate portfolio:
o 99% of the portfolio is A or B EPC rated, (100% A to C ratings) and therefore compliant with the minimum energy efficiency standards anticipated to apply from 2030
o Positive social impact from sector-leading real estate standards: 99% en suite wet-rooms; generous 47 sqm space per resident; sustainable rent of
· Rent collection remains robust at >98% collected to date. Rent cover on mature homes was stable, at 1.9x for the December 2023 quarter (most recent quarter of tenant data)
Kenneth MacKenzie, CEO of Target Fund Managers, commented:
"Target Healthcare's portfolio was ranked #1 in total returns within the
"We now have a mature and modern portfolio which is delivering consistently strong performance. Our current portfolio management initiatives include: a limited number of potential tenancy changes; select capital expenditure to enhance assets alongside our three development sites; and live opportunities to tighten-up the overall portfolio quality whilst reallocating some capital.
"We remain committed to our consistent, long-term approach to investment in this critically important sector."
EPRA NTA
The Group's unaudited EPRA NTA per share as at 31 March 2024 was
A balance sheet summary and an analysis of the movement in the EPRA NTA over the quarter is shown in the Appendix of this announcement.
Corporate Update
Portfolio performance
As at 31 March 2024, the Group's portfolio was valued at
Portfolio value increased by 2.6% over the quarter, comprising:
· a 1.4% like-for-like increase in the operational portfolio, reflecting an increase of 0.8% from inflation-linked rent reviews and rent-free unwinds alongside an increase of 0.6% from net yield tightening
· a 1.2% increase from capital expenditure, primarily associated with the five development properties of which two reached practical completion during the quarter
Contractual rental income increased by 3.7% over the quarter, comprising:
· a 0.8% like-for-like increase from 23 inflation-linked upwards-only rent reviews, with an average uplift of 3.9%
· a 2.9% increase from the completion of two forward funded developments which were leased on pre-agreed terms, with one home introducing a new tenant to the portfolio
The portfolio's WAULT remained unchanged at 26.0 years (31 December 2023: 26.0 years), with two new 35-year leases on the completed developments offsetting the passage of time on the existing portfolio.
The EPRA "topped-up" net initial yield was 6.19% based on an annualised contractual rent of
Portfolio update
During the quarter, the following asset management initiatives were undertaken:
· As previously announced, two of the Group's development sites in
· The conversion of a further 24 rooms to provide full en suite wet-room facilities was completed as part of ongoing asset enhancements, increasing the portfolio towards 100% en suite wet-rooms.
Debt facilities and swap arrangements
As at 31 March 2024, the Group's total borrowings were
89% of drawn debt is fully hedged:
·
·
·
· The remaining
The Group has access to a further
At 31 March 2024, the weighted average term to expiry on the Group's total committed loan facilities was 5.5 years (31 December 2023: 5.7 years) with the earliest maturity in November 2025.
Dividends
The Group paid its second interim dividend for the year ending 30 June 2024, in respect of the period from 1 October 2023 to 31 December 2023, of
Announcement of third interim dividend
The Company today declares its third interim dividend for the year ending 30 June 2024, in respect of the period from 1 January 2024 to 31 March 2024, of
Interim Property Income Distribution (PID): 1.428 pence per share
Interim ordinary dividend: nil
Ex-Dividend Date: |
16 May 2024 |
Record Date: |
17 May 2024 |
Payment Date: |
31 May 2024 |
The quarterly dividend reflects an annualised dividend of
The Company had 620,237,346 ordinary shares in issue at 31 March 2024 and has not issued or bought back any shares since that date.
Shareholders entitled to elect to receive distributions without deduction for withholding tax may complete the declaration form which is available on request from the Company through the contact details provided on its website www.targethealthcarereit.co.uk, or from the Company's registrar. Shareholders who qualify for gross payments are, principally,
LEI: 213800RXPY9WULUSBC04
ENDS
Enquiries:
Target Fund Managers Limited |
Tel: 01786 845 912 |
Kenneth MacKenzie |
|
Gordon Bland |
|
|
|
Stifel Nicolaus Europe Limited |
Tel: 020 7710 7600 |
Mark Young |
|
Rajpal Padam |
|
Catriona Neville |
|
|
|
FTI Consulting |
Tel: 020 3727 1000 |
Dido Laurimore |
TargetHealthcare@fticonsulting.com |
Richard Gotla |
|
Notes to editors:
The Group's portfolio at 31 March 2024 comprised 98 assets let to 33 tenants with a total value of
The Group invests in modern, purpose-built care homes that are let to high quality tenants who demonstrate strong operational capabilities and a strong care ethos. The Group builds collaborative, supportive relationships with each of its tenants as it believes working in this way helps raise standards of care and helps its tenants build sustainable businesses. In turn, that helps the Group deliver stable returns to its investors.
Important information
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the
APPENDIX
1. Analysis of movement in EPRA NTA
The following table provides an analysis of the movement in the unaudited EPRA NTA per share for the period from 1 January 2024 to 31 March 2024:
|
Pence per share |
|
EPRA NTA per share as at 31 December 2023 |
106.7 |
|
|
|
|
Revaluation gains / (losses) on investment properties |
2.0 |
|
Revaluation gains / (losses) on assets under construction^ |
0.2 |
|
Movement in revenue reserve |
1.5 |
|
Second interim dividend payment for the year ending 30 June 2024 |
(1.4) |
|
EPRA NTA per share as at 31 March 2024 |
109.0 |
|
Percentage change in the quarter |
2.2% |
|
The EPRA Best Practices Recommendations Guidelines state that companies should publish a set of three NAV metrics. The full set of EPRA NAV metrics are published in the Group's Annual Report. The Company intends to continue to announce the EPRA NTA on a quarterly basis.
At 31 March 2024, due to the valuation ascribed to the Group's interest rate derivative contracts used to hedge its exposure to variable interest rates, which are excluded from the calculation of the EPRA NTA, the unaudited NAV calculated under International Financial Reporting Standards was
^Consistent with standard valuation practice for assets under construction, the carrying value of these assets is calculated by the valuer through application of a discount to accumulated costs to date. This discount varies depending on factors such as the remaining development time. As the asset progresses towards completion, the discount that has been applied is unwound.
2. Summary balance sheet (unaudited)
|
|
|||
|
Mar-24 |
Dec-23 |
Sept-23 |
Jun-23 |
|
£m |
£m |
£m |
£m |
Property portfolio* |
934.8 |
911.1 |
890.3 |
868.7 |
Cash |
17.9 |
17.6 |
20.2 |
15.4 |
Net current assets / (liabilities)* |
(17.3) |
(14.7) |
(12.5) |
(6.2) |
Loans |
(259.0) |
(252.5) |
(243.0) |
(230.0) |
Net assets |
676.4 |
661.5 |
655.0 |
647.9 |
|
|
|
|
|
EPRA NTA per share (pence) |
109.0 |
106.7 |
105.6 |
104.5 |
*Properties within the portfolio are stated at the market value provided by the external valuer and the IFRS effects of fixed/guaranteed minimum rent reviews are not reflected.
3. External Valuer
The valuation of the property portfolio as at 31 March 2024 was conducted by CBRE Limited.
The next quarterly valuation of the property portfolio will be conducted by CBRE Limited during July 2024 and the unaudited EPRA NTA per share as at 30 June 2024 is expected to be announced in July 2024.
4. EPRA NIY profiles and unwind of rent-free periods
The Group currently has two assets with a rent-free / reduced initial rent period. As these unwind, assuming no other changes including inter alia the portfolio valuation or rental profile, the EPRA yield profiles for the portfolio will be as follows:
|
|
31 March 2024 |
30 June 2024 |
30 September 2024 |
EPRA "topped-up" NIY |
|
6.19% |
6.19% |
6.19% |
EPRA NIY |
|
6.06% |
6.10% |
6.19% |
Contractual rent (£m) |
|
60.1 |
60.1 |
60.1 |
Passing rent (£m) |
|
58.8 |
59.2 |
60.1 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.